I think your understanding of statistical analysis in medical trials is dominating the movement becasue we are an unsophisticated market the unsophisticated are the first to move. Those who believe otherwise are happy enough to take the stock.
There will be professional analysis available soon enough to highlight who's right
Ann: Positive interim analysis of DMX-200 phase II data-DXB.AX, page-43
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $267.5M | |||
| Open | High | Low | Value | Volume |
| 49.0¢ | 49.0¢ | 47.5¢ | $301.0K | 626.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 42532 | 48.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.5¢ | 41182 | 9 |
View Market Depth
| Last trade - 11.38am 17/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |